* * * * * * * * * * * * * * * * * * * * * * * * * * * * NOTICE OF GRANT AWARD * * * * * * * * * * * * * * * * * * * * * * * * *
Exhibit 10.35
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * NOTICE OF GRANT AWARD * * * * * * * * * * * * * * * * * * * * * * * * *
| RESEARCH PROJECT COOPERATIVE AGREEMENT
Department of Health and Human Services National Institutes of Health NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS |
Issue Date: 06/21/2004 |
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
Grant Number: 1 U01 AI057264-01 (Revised)
Principal Investigator: ▇▇▇▇▇, ▇▇▇▇▇▇ ▇. MD
Project Title: Pulmonary innate immune activation for bioterror defense
VP & CONTROLLER
▇▇▇▇▇ PHARMACEUTICAL GROUP, INC
▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇ ▇▇▇
WELLESLEY, MA 02481
UNITED STATES
Budget Period: 09/15/2003 - 02/29/2004
Project Period: 09/15/2003 - 02/28/2006
Dear Business Official:
The National Institutes of Health hereby revises this award to reflect an increase in the amount of $46,248 (see “Award Calculation” in Section I and “Terms and Conditions” in Section III) to ▇▇▇▇▇ PHARMACEUTICAL GROUP, INC. in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 31 USC 6305 & 6306 and is subject to terms and conditions referenced below.
Acceptance of this award including the Terms and Conditions is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.
Award recipients are responsible for reporting inventions derived or reduced to practice in the performance of work under this grant. Rights to inventions vest with the grantee organization provided certain requirements are met and there is acknowledgement of NIH support. In addition, recipients must ensure that patent and license activities are consistent with their responsibility to make unique research resources developed under this award available to the scientific community, in accordance with NIH policy. For additional information, please visit ▇▇▇▇://▇▇▇.▇▇▇▇▇▇▇.▇▇▇.
If you have any questions about this award, please contact the individual(s) referenced in the information below.
| Sincerely yours, |
| /s/ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ |
| ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇ Management Officer |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
See additional information below
SECTION I - AWARD DATA - 1 U01 AI057264-01 (Revised)
AWARD CALCULATION (U.S. Dollars):
| Salaries and Wages |
$ | 143,767 | |
| Fringe Benefits |
$ | 33,066 | |
| Personnel Costs |
$ | 176,833 | |
| Consultant Services |
$ | 7,500 | |
| Supplies |
$ | 171,675 | |
| Travel Costs |
$ | 7,500 | |
| Other Costs |
$ | 750 | |
| Consortium/Contractual Cost |
$ | 678,022 | |
| Federal Direct Costs |
$ | 1,042,280 | |
| Federal F&A Costs |
$ | 168,563 | |
| APPROVED BUDGET |
$ | 1,210,843 | |
| TOTAL FEDERAL AWARD AMOUNT |
$ | 1,210,843 | |
| AMOUNT OF THIS ACTION (FEDERAL SHARE) |
+$ | 46,248 | |
Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project, is as follows.
| 02 |
$ | 2,324,383 | |
| 03 |
$ | 2,394,113 |
FISCAL INFORMATION:
CFDA Number: 93.855
EIN: 1061506689A1
Document Number: UAI057264A
| IC / CAN / FY2003 / FY2004 / FY2005
| ||||||||||
| AI / 8460926 / 1,210,843 / 2,324,383 / 2,394,113 | ||||||||||
NIH ADMINISTRATIVE DATA:
PCC: I2B / OC: 41.4L /Processed: GORDONJ 040616 0102
SECTION II - PAYMENT/HOTLINE INFORMATION - 1 U01 AI057264-01 (Revised)
For Payment and HHS Office of Inspector General Hotline Information, see the NIH Home
Page at ▇▇▇▇://▇▇▇▇▇▇.▇▇▇.▇▇▇/▇▇▇▇▇▇/▇▇▇▇▇▇/▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇
SECTION III - TERMS AND CONDITIONS - 1 U01 AI057264-01 (Revised)
This award is based on the application submitted to, and as approved by, the NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:
a. The grant program legislation and program regulation cited in this Notice of Grant Award.
b. The restrictions on the expenditure of federal funds in appropriations acts, to the extent those restrictions are pertinent to the award.
c. 45 CFR Part 74 or 45 CFR Part 92 as applicable.
d. The NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
e. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.
(see NIH Home Page at ▇▇▇▇://▇▇▇▇▇▇.▇▇▇.▇▇▇/▇▇▇▇▇▇/▇▇▇▇▇▇/▇▇▇▇▇▇▇▇▇▇▇▇▇▇▇.▇▇▇ for certain references cited above.)
Carry over of an unobligated balance into the next budget period requires Grants Management Officer prior approval.
Treatment of Program Income:
Additional Costs
SECTION IV - NIAID SPECIFIC TERMS OF AWARD -
REVISED AWARD: This revised Notice of Grant Award (NGA) is issued to adjust facilities and administrative (F&A) costs to reflect the negotiated F&A rate dated 04/27/2004. Future year has been adjusted.
Supersedes NGA issued 03/03/2004.
* * * * * * * * * * * * * *
Direct costs awarded are based at the committed level.
This award is subject to the Terms and Conditions of Award as set forth in the SPECIAL REQUIREMENTS section of RFA/PA AI-03-025, NIH Guide to Grants and Contracts, 11/14/2002. These special terms and conditions are incorporated in this award by reference.
Copies of the RFA may be accessed at the following Internet address: ▇▇▇▇://▇▇▇.▇▇▇.▇▇▇/▇▇▇▇▇▇/▇▇▇▇▇/▇▇▇▇▇.▇▇▇▇
None of the funds in this award shall be used to pay the salary of an individual at a rate in excess of Executive Level I of the Federal Executive Payscale. The application for this project proposed a salary at a rate greater than Executive Level I per year for ▇▇. ▇▇▇▇▇ and ▇▇. ▇▇▇▇▇▇▇. This award and future year commitments have been adjusted accordingly.
▇▇▇▇▇ ▇. ▇▇▇▇▇▇, Program Official
Phone: ▇▇▇-▇▇▇-▇▇▇▇ Email: ▇▇▇▇▇▇▇@▇▇▇▇▇.▇▇▇.▇▇▇ Fax: ▇▇▇-▇▇▇-▇▇▇▇
▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, Grants Specialist
Phone: ▇▇▇-▇▇▇-▇▇▇▇ Email: ▇▇▇▇▇@▇▇▇.▇▇▇ Fax: ▇▇▇-▇▇▇-▇▇▇▇
SPREADSHEET
GRANT NUMBER: 5 U01 AI057264-02 (Revised)
P.I.: ▇▇▇▇▇, ▇▇▇▇▇▇ ▇.
INSTITUTION: ▇▇▇▇▇ PHARMACEUTICAL GROUP, INC.
| YEAR 02 |
YEAR 03 | |||
| Salaries and Wages |
296,159 | 305,044 | ||
| Fringe Benefits |
68,116 | 70,159 | ||
| Personnel Costs |
364,275 | 375,203 | ||
| Consultant Services |
15,450 | 15,914 | ||
| Supplies |
353,651 | 364,261 | ||
| Travel Costs |
15,450 | 15,914 | ||
| Other Costs |
1,545 | 1,591 | ||
| Consortium/Contractual Cost |
1,386,419 | 1,428,009 | ||
| TOTAL FEDERAL DC |
2,136,790 | 2,200,892 | ||
| TOTAL FEDERAL F&A |
345,899 | 356,276 | ||
| TOTAL COST |
2,482,689 | 2,557,168 | ||
| YEAR 02 |
YEAR 03 |
|||||
| F&A Cost Rate 1 |
36.00 | % | 36.00 | % | ||
| F&A Cost Base 1 |
296,159 | 305,044 | ||||
| F&A Costs 1 |
106,617 | 109,816 | ||||
| F&A Cost Rate 2 |
13.00 | % | 13.00 | % | ||
| F&A Cost Base 2 |
1,840,631 | 1,895,848 | ||||
| F&A Costs 2 |
239,282 | 246,460 | ||||